1. Indications and Usage
\nLocally Advanced or Metastatic Gastric Cancer (GC\/GEJC):
\nIndicated for the treatment of adult patients with HER2-overexpressing (IHC 2+ or 3+), locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have received two or more prior systemic chemotherapy regimens.
\nUrothelial Cancer (UC):
\nIndicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously been treated with a PD-1 or PD-L1 inhibitor.
\nBreast Cancer (BC):
\nIndicated for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer with liver metastases who have received prior trastuzumab and a taxane.
\n2. Dosage and Administration
\nRoute of Administration:
\nIntravenous Infusion ONLY. Do not administer as an IV push or bolus.
\nRecommended Dosage:
\nFor Gastric Cancer: 2.5 mg\/kg administered intravenously once every 2 weeks (Q2W).
\nFor Urothelial Cancer \/ Breast Cancer: 2.0 mg\/kg administered intravenously once every 2 weeks (Q2W).
\nAdministration Instructions:
\nInfusion Time: Administer via intravenous drip over approximately 60 minutes (range 30-90 minutes).
\nPremedication: Not routinely required but monitor for infusion reactions.
\n3. Mechanism of Action
\nADC Technology:
\nDisitamab vedotin is an antibody-drug conjugate targeting HER2.
\nPayload Release:
\nUpon binding to HER2 on tumor cells, the drug is internalized and degraded in lysosomes, releasing the active cytotoxic payload MMAE (monomethyl auristatin E). MMAE binds to tubulin, inhibiting its polymerization, which leads to cell cycle arrest and apoptosis.
\n4. Safety and Warnings
\nPeripheral Neuropathy:
\nMay cause sensory neuropathy (numbness, hypoesthesia). Monitor for new or worsening neurological symptoms. Dose interruption or reduction is recommended for Grade \u2265 2 neuropathy.
\nOcular Toxicity:
\nMonitor for signs of ocular toxicity (e.g., blurred vision, dry eye).
\nInfusion-Related Reactions:
\nMonitor patients during and after infusion for signs of anaphylaxis or infusion reactions (fever, chills, dyspnea).
\n5. Adverse Reactions
\nMost Common:
\nElevated transaminases (ALT\/AST), decreased white blood cell count, decreased neutrophil count, sensory neuropathy, fatigue, alopecia, nausea, and decreased appetite.
\n6. Drug Interactions
\nP-gp Inhibitors:
\nAvoid concomitant use of strong P-glycoprotein (P-gp) inhibitors, as they may increase the exposure of MMAE and the risk of toxicity.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Disitamab Vedotin (Available in 60 mg vials).
\nStorage:
\nStore in a refrigerator at 2-8\u00b0C in the original carton to protect from light. Do not freeze.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u7231\u5730\u5e0c\u00ae(Aidixi\u00ae)
\nGeneric Name: Disitamab Vedotin
\nStrength: 60mg per vial, 1 vial per box
\nManufacturer: RemeGen Co., Ltd.
\nMarketing Authorization Holder: RemeGen Co., Ltd.
\nApproval Date in China: June 9, 2021
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 S20210017
\nStorage: Store and transport at 2\u2103~8\u2103, protected from light, do not freeze. After reconstitution and dilution, use promptly. Keep out of reach of children.<\/p>\n
Price&Cost:Contact Us now for the best price of Disitamab Vedotin(Aidixi\uff09<\/p>\n","protected":false},"featured_media":3427,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[25,73],"product_tag":[],"class_list":["post-3426","product","type-product","status-publish","has-post-thumbnail","product_cat-injection","product_cat-chinese-innovative-drug","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n